Francis Wheeler

Cooley advised the underwriters of Upstream Bio, a clinical-stage biotech developing a monoclonal antibody to target respiratory disorders, on its upsized $293 million initial public offering.

Cooley advised the underwriters of Zhejiang Taimei Medical Technology (Taimei), a digital solution provider focused on the pharmaceutical and medical device industry in China, on its HK$335.1 million initial public offering.

Cooley advised Uber Technologies on its $5 billion investment-grade revolving credit facility.

Cooley advised Snowflake, the artificial intelligence (AI) Data Cloud company, on its private placement of $2.3 billion aggregate principal amount of convertible senior notes, consisting of $1.15 billion principal amount of convertible senior notes due 2027 and $1.15 billion aggregate principal amount of convertible senior notes due 2029, which includes the exercise in full of the initial purchasers’ options to purchase an additional $150 million principal amount of 2027 notes and $150 million principal amount of 2029 notes. 

Cooley advised the underwriters of BioAge Labs, a clinical-stage biotechnology company that is harnessing the biology of human aging to develop novel targets and therapies for metabolic diseases, on its $198 million initial public offering.